8 Monster Stock Market Predictions For The Week of November 18

November 17

Independent macro and options research, published every trading day — $85/mo or $750/yr

Subscribe →

Stock mentions: AMD, MSFT, BYND, MU, BIIB, ACAD

Macro mentions: SPY, IWM

MICHAEL KRAMER AND THE CLIENTS OF MOTT CAPITAL OWN ACAD AND MSFT

For the week of November 18

MACRO

S&P 500 (SPY)

Stocks will look to continue where they left off last week, and likely continue to work there way towards 3,150 on the S&P 500. The market continues to feel like it wants to go up, pretty much holding steady on negative headlines, and pushing higher on positive headlines.

More in premium content about the week ahead – Stocks Are Breaking Out On Hopes Of A Return To Global Growth

S&P 500 , spy

Russel 2000 (IWM)

Meanwhile, we will continue to wait for the Russell 2000 to break out. The index has been unable to get above 1,600 for some time.

russell, rut

STOCKS

AMD (AMD)

AMD seems to be on a course that will end up sending the stock back to prices not seen since 2006, at roughly $42.

amd, amd

Microsoft (MSFT)

Microsoft is likely to continue to push higher this week with the potential to make it to around $152 in the not to distance future.

microsoft, msft

Intel (INTC)

Intel is testing a break out of its own around $59 with the potential for a push higher to prices not seen since September 2000 at $64.

intel, intc

Beyond Meat (BYND)

Beyond Meat has acted very well at support around $78. I thought it would fill the gap $100 last week; it stands a better chance this week.

bynd, beyond meat

Micron (MU)

Micron failed at resistance at $48.75 this past week, and it doesn’t bode well for my call for the stock to rise to $53 I noted on November 5 – Micron Is Breaking Out

micron, mu

Acadia (ACAD)

Acadia finally made it to resistance at $48.10; now, it needs to break out to get back to it all-time $52. The way the stock traded last week on strong volume, one has to think there is news coming soon.

acadia, acad

Biogen (BIIB)

Biogen keeps slipping lower, and now it is at support at $280. The big question is if it fills that gap down at $225. Ouch. It may. Maybe not this week, but if breaks support, watch out.

biogen, biib

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future results.

This report contains independent commentary to be used for informational and educational purposes only. Michael Kramer is a member and investment adviser representative with Mott Capital Management. Mr. Kramer is not affiliated with this company and does not serve on the board of any related company that issued this stock. All opinions and analyses presented by Michael Kramer in this analysis or market report are solely Michael Kramer’s views. Readers should not treat any opinion, viewpoint, or prediction expressed by Michael Kramer as a specific solicitation or recommendation to buy or sell a particular security or follow a particular strategy. Michael Kramer’s analyses are based upon information and independent research that he considers reliable, but neither Michael Kramer nor Mott Capital Management guarantees its completeness or accuracy, and it should not be relied upon as such. Michael Kramer is not under any obligation to update or correct any information presented in his analyses. Mr. Kramer’s statements, guidance, and opinions are subject to change without notice. Past performance is not indicative of future results. Neither Michael Kramer nor Mott Capital Management guarantees any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment commentary presented in this analysis. Strategies or investments discussed may fluctuate in price or value. Investments or strategies mentioned in this analysis may not be suitable for you. This material does not consider your particular investment objectives, financial situation, or needs and is not intended as a recommendation appropriate for you. You must make an independent decision regarding investments or strategies in this analysis. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Before acting on information in this analysis, you should consider whether it is suitable for your circumstances and strongly consider seeking advice from your own financial or investment adviser to determine the suitability of any investment.